Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is among the hidden penny stocks to invest in. As of June 10, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was trading near the low levels reported on June 3, before the stock appreciated following the Australian approval of Amtagvi. The stock has returned to its pre-approval levels.

On June 4, TheFly reported that Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has received conditional approval of Amtagvi from the Therapeutic Goods Administration of Australia. This marks the third marketing authorization for Amtagvi, underscoring a huge step forward in a market with the highest rate of melanoma globally.

Overall, 80% of the analysts are bullish on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), with the remaining 20% neutral. On May 8, Chardan trimmed the price target on the company from $16 to $14 and reiterated a Buy rating. In a research note, the analyst attributed this model readjustment to the revised Amtagvi launch guidance. Management now forecasts Q2 Amtagvi revenue to be between $79 million and $81 million. With this potential, the company has secured a spot among the hidden penny stocks to invest in.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), incorporated in 2007, is a California-based commercial-stage biopharmaceutical company specializing in cell therapies for metastatic melanoma and other solid tumor cancers.

While we acknowledge the risk and potential of IOVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IOVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1